Remember
 
 
Watch for Reactions to Your Posts or React Below to Other's Posts. Discover Stocks and Market Data.

Fighting Cancer Stocks & ETFs, Headlines, and Posts Bucket Watchlist of Fighting Cancer Stocks, ETFs, Headlines and Posts

Types of Stocks and ETFs: cancer, oncology, pharma, etc.















Watchlist of Stocks and ETFs Based on Theme: Companies Related to Fighting Cancer.

Generated with SpeculatingStocks Stock Theme Analytics Algorithmâ„¢ - More Bucket Watchlists of Stocks.

Important Note: Most of the stocks and ETFs in this list directly relate to fighting cancer; however, a few may just somewhat depend and/or be indirectly related to fighting cancer. As always complete your own due diligence.


Fighting Cancer Stocks & ETFs


Symbol
Company / ETF Name
Market Cap





















































345.879M
















366.288M




















185.431B
























216.135B






























































187.349B























































Recent Fighting Cancer Headlines





Recent Fighting Cancer Posts (Pulses)




02/23/2018: $FATE Fate Therapeutics awarded a $4.0M grant to advance FT516 into a first-in-human clinical trial. FT516 is being developed by Fate Therapeutics as an off-the-shelf engineered NK cell cancer immunotherapy. -- Go to this Pulse Post



02/15/2018: $MYGN Myriad Genetics announced comparative analysis of commercially available prognostic breast cancer tests in patients with early-stage breast cancer in JAMA Oncology. -- Go to this Pulse Post



02/13/2018: $MBRX Moleculin Biotech entered into an agreement with Emory University to enable expanded cancer research on Moleculin's WP1066 molecule for the possible treatment of medulloblastoma, a pediatric malignant primary brain tumor. -- Go to this Pulse Post



02/05/2018: $VAR Varian Medical acquired privately-held Mobius Medical Systems, a radiation oncology Quality Assurance (QA) software company; terms not disclosed. -- Go to this Pulse Post



02/05/2018: $BMY Bristol-Myers beat by $0.01, beat on revenue; guided FY18 EPS in-line; Pivotal Phase 3 CheckMate -227 study demonstrated superior progression-free survival (pfs) with the Opdivo Plus Yervoy Combination versus chemotherapy in first-line non-small cell lung cancer (NSCLC) patients with high... -- Go to this Pulse Post



01/-0/2018: $ITUS ITUS presented 'positive' data that augments data presented back in December 2016 from its early cancer detection technology on January 26 at the ASCO-SITC. -- Go to this Pulse Post



01/-0/2018: $AAAP Advanced Accelerator Applications (Being acquired by Novartis (NVS)) received FDA approval for Lutathera for the treatment of a type of cancer that affects the pancreas or gastrointestinal tract called gastroenteropancreatic neuroendocrine tumors. -- Go to this Pulse Post



01/-0/2018: $ADXS Advaxis announced publication of data from study evaluating ADXS11-001 in combination with chemoradiation as a treatment for high-risk, locally advanced anal cancer in the International Journal of Radiation Oncology. -- Go to this Pulse Post



01/-0/2018: $BLRX BioLineRx announced publication of data showing that BL-8040 augments the ability of the immune system to fight cancer by increasing the infiltration of anti-tumor-specific T-cells into the tumor microenvironment. -- Go to this Pulse Post



01/-0/2018: $RNN Rexahn Pharmaceuticals announced the final data from a Phase IIa Clinical Trial of RX-3117 in metastatic pancreatic cancer were presented at the ASCO GI 2018 annual meeting. -- Go to this Pulse Post



01/-0/2018: $NCNA NuCana announced 'promising' clinical data on NUC-1031 as front-line treatment of advanced biliary tract cancer (shares halted). -- Go to this Pulse Post



01/-0/2018: $DSNKY Daiichi Sankyo presented updated phase 1 safety and efficacy data for DS-8201 in a subgroup of patients with HER2-expressing gastric cancer previously treated with trastuzumab and chemotherapy. -- Go to this Pulse Post



01/-0/2018: $APTO is a small $75M clinical-stage oncology company having a big day. It's worth following. -- Go to this Pulse Post



01/-0/2018: $APOP Cellect Biotechnology signed an agreement with the Hadassah Medical Center to conduct clinical trials on cancer patients in Cellect's ongoing Phase I/II study. -- Go to this Pulse Post



01/-0/2018: $MTP Midatech Pharma announced approval of the investigational new drug application from the FDA to conduct a study of MTX110 for the treatment of the fatal childhood brain cancer DIPG. -- Go to this Pulse Post



01/-0/2018: $ADAP Adaptimmune Therapeutics announced data from its studies of SPEAR T-cells targeting MAGE-A10, one in non-small cell lung cancer (NSCLC) and a triple tumor study in bladder, melanoma, and head & neck cancers. -- Go to this Pulse Post



01/-0/2018: $EXEL Exelixis entered into an exclusive collaboration and license agreement with StemSynergy Therapeutics for the discovery and development of novel oncology compounds targeting Casein Kinase 1 alpha. -- Go to this Pulse Post



01/-0/2018: $ILMN Illumina and KingMed announced an agreement to jointly develop novel oncology and hereditary disease testing applications utilizing Illumina's next-generation sequencing technology in China. -- Go to this Pulse Post



01/-0/2018: $FSNUY Fresenius SE Kabi launched IV cancer drug in the U.S.. -- Go to this Pulse Post



01/-0/2018: $MRK Merck announced that KEYTRUDA has been approved by the Japanese Ministry of Health, Labor and Welfare for the treatment of patients with radically unresectable urothelial carcinoma who progressed after cancer chemotherapy. -- Go to this Pulse Post